| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.24 | 5e-10 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-09 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.39 | 4e-09 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.19 | 3e-08 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.18 | 1e-07 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-07 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.16 | 7e-07 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-07 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |